Wednesday, November 7, 2012

Cerus to pursue U.S. approval of plasma safety system

The Food and Drug Administration will allow Cerus Corp. to submit a premarket application toward approval of its blood safety system, the company said Wednesday.
More than 80 blood centers in 17 European and Middle Eastern countries use the Concord-based company's (NASDAQ: CERS) Intercept system to neutralize pathogens in platelets and/or plasma, the clear yellowish liquids essential for clotting. But because two studies failed and a collaboration with Baxter fell apart, Cerus hasn't been able to win U.S. approval for its system for screening platelets, plasma or red blood cells.

No comments:

Post a Comment